Interestingly, our data on the capacity of sunitinib to increase PD-L1 expression on sarcoma cells revealed a potential role of sunitinib as an immunomodulatory agent and prompted us to further characterize in vitro its effect on different immune cell subsets. This evidence concerns the gene CD274 and sarcoma.